digital currency risks- Top Block

Judging from the market performance, the average growth rate of 41 key sector stocks since September 18 is close to 56%, far outperforming the performance of the broader market in the same period. Among them, two stocks of Xinxiangwei and SMIC doubled. Xinxiangwei's main business focuses on the research, development, design and sales of display chips, and is committed to providing complete display chip system solutions.Among them, the market value of chip leader SMIC A shares exceeded 170 billion yuan, ranking first. According to the data, SMIC is one of the world's leading integrated circuit wafer foundry enterprises, and it is a professional wafer foundry enterprise with advanced technology, the largest scale, the most complete supporting services and transnational operation.

Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.

In the secondary market, the concept stocks of M&A and restructuring rose strongly, and the restructuring index rose nearly 63% since September 24th.It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.